Sonoma Pharmaceuticals (SNOA) Cash from Financing Activities (2010 - 2026)

Sonoma Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $387000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 59.92% year-over-year to $387000.0 in Q1 2026; TTM through Mar 2026 was $477000.0, a 84.26% decrease from a year earlier, with the FY2026 full-year figure at $477000.0, down 84.26% from the prior year.
• Cash from Financing Activities grew to $387000.0 in Q1 2026 per SNOA's latest filing, from $210000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $3.4 million in Q1 2023 and bottomed at -$387000.0 in Q2 2022.
• The 5-year median for Cash from Financing Activities is $222000.0 (2022), against an average of $464352.9.
• Across the five-year window, Cash from Financing Activities slumped 168.68% in 2022 and soared 1418.92% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$318000.0 in 2022, then soared by 514.47% to $1.3 million in 2023, then slumped by 46.28% to $708000.0 in 2024, then sank by 70.34% to $210000.0 in 2025, then soared by 84.29% to $387000.0 in 2026.
• Per Business Quant, the three latest SNOA Cash from Financing Activities figures stand at $387000.0 (Q1 2026), $210000.0 (Q4 2025), and -$62000.0 (Q3 2025).